AmVac AG Granted a European Patent for ProstaVac

23-Jun-2010 - European patent EP 1272216B1 with the title "Vaccine consisting of lactobacilli for the treatment of inflammation of the prostate and benign prostatic hyperplasia" was granted by the European Patent Office on9.6.2010. AmVac AG holds a licence for the above patent. Granting of the patent is a ...

Protox announces positive Phase 2b BPH results

13-Jan-2010 - Protox Therapeutics Inc. announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH). The study achieved its primary clinical endpoint of a statistically ...

Protox completes enrollment of Phase 2b BPH trial

10-Sep-2009 - Protox Therapeutics Inc. announced that it has completed patient enrollment in its multi-centre, double-blinded, placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in males with moderate to severe benign prostatic hyperplasia (BPH). TRIUMPH is the third BPH clinical trial of ...

Vantia Therapeutics’ pipeline continues to mature

VA106483 completes Phase IIa trial and VA111913 completes Phase I dosing

26-Mar-2009 - Vantia Therapeutics announced further clinical trial progress with its two lead development compounds, VA106483 for nocturia associated with benign prostatic hypertrophy (BPH) and VA111913 for dysmenorrhoea. The Phase IIa trial of VA106483 has completed, while dosing is complete in the Phase I ...

PCA3 Test May Help Distinguish Aggressive Prostate Cancer

The PCA3 Test May Help Distinguish Between Benign and Aggressive

31-Oct-2008 - The number of prostate cancer cases is increasing rapidly. Fortunately not all these tumours need to be operated - some are slow growing or indolent. The question remains: how do we reliably establish which tumour is aggressive and which is not? The answer may well be given by the PCA3 (Prostate ...

Protox doses first patient in Phase 2 BPH clinical trial

19-May-2008 - Protox Therapeutics Inc. announced the enrolment and successful dosing of the first patient in a Phase 2 clinical trial evaluating PRX302 to treat benign prostatic hyperplasia (BPH), or enlarged prostate. "This milestone sets the stage for a very exciting time for Protox this year as we embark ...

AEterna Zentaris: First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia

16-May-2008 - AEterna Zentaris Inc. reported dosing has commenced in the safety study of the Company's Phase 3 program with cetrorelix in benign prostatic hyperplasia (BPH). Cetrorelix, a novel investigational luteinizing hormone-releasing hormone (LHRH) antagonist, is the Company's flagship product ...

Protox announces positive long-term data from BPH study

21-Apr-2008 - Protox Therapeutics Inc. announced positive results from its Phase 1 study evaluating PRX302 in patients with benign prostatic hyperplasia (BPH), a common and bothersome urological condition among the aging male population. The results indicate that promising signs of therapeutic activity ...

Protox announces positive final results from BPH study

07-Jan-2008 - Protox(TM) Therapeutics Inc. announced positive final results from its Phase 1 study evaluating PRX302 in patients with benign prostatic hyperplasia (BPH), a common condition among the aging male population. The trial results indicate that PRX302 is safe and well tolerated and shows very ...

Nymox Reports Completion of Large New 2 Year Follow-up Study of NX-1207 for BPH

16-Nov-2007 - Nymox Pharmaceutical Corporation announced completion of a large new 2 year follow-up study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of over one hundred subjects involved in the Company's Phase 2 U.S. clinical trial initiated in 2005. Individuals ...